Independent Clinical Study Results for the UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System to be Presented at the American Society for Plastic Surgeons Annual Meeting



    YOQNEAM, ISRAEL & SAN RAMON, CALIF., October 30 /CNW/ - Results of an
independent multi-treatment clinical study of the UltraShape Contour I, the
first clinically proven non-invasive focused ultrasound solution for fat
reduction and body contouring, will be presented at the American Society for
Plastic Surgeons (ASPS) annual meeting on October 30, 2007 in Baltimore, Md.
The presentation is entitled "Non-invasive Ultrasonic Selective Fat Cell Lysis
and Body Contouring" and will take place during the scientific session "Body
Contouring: Are We There Yet?"

    London-based plastic surgeon, Chris Inglefield, BSC, FRCS (Plast), will
present his two-and-one-half years of clinical experience and results of his
118 patient clinical study using the UltraShape system to reduce localized fat
deposits in the abdomen, flanks, hips, inner and outer thighs, back rolls,
buttocks and male chest. Study participants received a series of three
treatments, one month apart, which resulted in an average three-inch (7.5cm)
reduction in circumference for all body areas, and an average 2.5-inch (6.3cm)
reduction in circumference for the abdomen, hips and lateral thighs. The study
also found that ninety-three percent (93%) of patients described their results
as either "good" or "excellent." Additionally, there were no patient-related
adverse events.

    "The excellent patient satisfaction that I've seen with the UltraShape
procedure over the past two years confirms that this technology is safe and
effective, and answers an unmet patient need for non-invasive fat reduction
with no pain or downtime," said Inglefield. "The convenient 'walk-in,
walk-out' procedure allows patients to see measurable circumference reduction
and body contouring without the hassle and risk associated with other, more
invasive approaches - they literally receive the treatment and then
immediately resume their daily routine."

    The study, conducted at London Bridge Plastic Surgery in London, measured
results of more than 118 women (n=86) and men (n=32) with a mean age of 38
years old. Selected patients had a body mass index of less then 30, a healthy,
motivated attitude toward exercise and diet, localized fat deposits and a
desire for non-invasive fat-reduction and body contouring.

    "As we continue to add to our extensive body of clinical data for
UltraShape we are encouraged by the positive response from both patients and
physicians," said Rodger Stewart, President and Chief Executive Officer of
UltraShape, Inc. "There is an increasing demand for non-invasive fat reduction
and body contouring, and UltraShape offers a safe, effective option without
downtime or required maintenance treatments."

    About the UltraShape Contour I

    The UltraShape Contour I system, based on patented focused ultrasound
technology, is the first scientifically and clinically proven non-invasive fat
reduction and body contouring solution for both men and women. The device
produces mechanical, non-thermal, acoustic effects which targets and
selectively destroys fat cells, leaving surrounding critical structures such
as skin, blood vessels, nerves, and connective tissue intact. The UltraShape
procedure is guided by proprietary real-time tracking and guidance technology
designed to deliver smooth, uniform body contouring results. The software
guarantees adherence to a pre-determined treatment algorithm minimizing risk
of contour irregularities, a common side effect of liposuction. The UltraShape
procedure is performed during a convenient, "walk-in, walk-out" session
carried out in an office-based environment; it requires no anesthesia or
sedation, and the vast majority of patients report no pain or discomfort.
After treatment, patients immediately resume their daily routines with no need
for maintenance treatments. The UltraShape procedure is available in 47
countries and over 45,000 patient treatments have been performed worldwide
with high patient satisfaction. The UltraShape Contour I received the CE Mark
in 2005 and a medical device license from Health Canada in 2007. The
UltraShape Contour I was selected as the Ultrasonic Industry Association's
(UIA) New Product for 2007, an award recognizing its innovative use of
ultrasound technology. The UltraShape Contour I system is not available for
sale in the United States.

    About UltraShape

    UltraShape is redefining aesthetic medicine by developing, manufacturing
and marketing innovative non-invasive technologies for body contouring. The
company is dedicated to providing clinically proven safe and effective
solutions that enhance the lives of patients worldwide. The UltraShape
proprietary non-invasive body contouring technology is based on focused
ultrasound that targets and selectively disrupts fat cells without affecting
surrounding structures. Founded in 2000, UltraShape is a privately held and
venture backed company with offices in the United States, Israel, France,
United Kingdom, and Italy. For more information visit www.ultrashape.com.




For further information:

For further information: UltraShape Abigail Marks, +972-4-909-9260
abigail@ultrashape.com or FischerHealth Paula Moggio, 310-577-7870 x151
pmoggio@fischerhealth.com or Gitam Porter Novelli Jessica Fishman,
+972-3-576-5798 jessica@gitam.co.il

Organization Profile

ULTRASHAPE

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890